Characterization	O
of	O
Contributing	O
Factors	O
to	O
Variability	O
in	O
Morphine	B:C0026549
Clearance	O
Through	O
PBPK	O
Modeling	I:C0201734
Implemented	O
With	O
OCT1	O
Transporter	I:C0291786
.	O

Characterization	O
of	O
Contributing	O
Factors	O
to	O
Variability	O
in	O
Morphine	O
Clearance	B:C1382187
Through	O
PBPK	O
Modeling	I:C0201734
Implemented	O
With	O
OCT1	O
Transporter	I:C0291786
.	O

Characterization	O
of	O
Contributing	O
Factors	O
to	O
Variability	O
in	O
Morphine	O
Clearance	O
Through	O
PBPK	B:C0201734
Modeling	I:C0201734
Implemented	O
With	O
OCT1	O
Transporter	I:C0291786
.	O

Characterization	O
of	O
Contributing	O
Factors	O
to	O
Variability	O
in	O
Morphine	O
Clearance	O
Through	O
PBPK	O
Modeling	I:C0201734
Implemented	O
With	O
OCT1	B:C0291786
Transporter	I:C0291786
.	O

Morphine	B:C0026549
shows	O
large	O
interindividual	O
variability	O
in	O
its	O
pharmacokinetics	O
;	O
however	O
,	O
the	O
cause	O
of	O
this	O
has	O
not	O
been	O
fully	O
addressed	O
.	O

The	O
variability	O
in	O
morphine	B:C0026549
disposition	O
is	O
considered	O
to	O
be	O
due	O
to	O
a	O
combination	O
of	O
pharmacogenetic	O
and	O
physiological	O
determinants	O
related	O
to	O
morphine	O
disposition	O
.	O

The	O
variability	O
in	O
morphine	O
disposition	O
is	O
considered	O
to	O
be	O
due	O
to	O
a	O
combination	O
of	O
pharmacogenetic	O
and	O
physiological	O
determinants	O
related	O
to	O
morphine	B:C0026549
disposition	O
.	O

We	O
previously	O
reported	O
the	O
effect	O
of	O
organic	B:C0291786
cation	I:C0291786
transporter	I:C0291786
(	O
OCT1	O
)	O
genotype	O
on	O
morphine	O
disposition	O
in	O
pediatric	O
patients	O
.	O

We	O
previously	O
reported	O
the	O
effect	O
of	O
organic	O
cation	I:C0291786
transporter	I:C0291786
(	O
OCT1	B:C0291786
)	O
genotype	O
on	O
morphine	O
disposition	O
in	O
pediatric	O
patients	O
.	O

We	O
previously	O
reported	O
the	O
effect	O
of	O
organic	O
cation	I:C0291786
transporter	I:C0291786
(	O
OCT1	O
)	O
genotype	O
on	O
morphine	B:C0026549
disposition	O
in	O
pediatric	O
patients	O
.	O

To	O
further	O
explore	O
the	O
underlying	O
mechanisms	O
for	O
variability	O
arising	O
from	O
relevant	O
determinants	O
,	O
including	O
OCT1	B:C0291786
,	O
a	O
physiologically	O
based	O
pharmacokinetic	O
(	I:C0201734
PBPK	I:C0201734
)	I:C0201734
model	I:C0201734
of	O
morphine	O
was	O
developed	O
.	O

To	O
further	O
explore	O
the	O
underlying	O
mechanisms	O
for	O
variability	O
arising	O
from	O
relevant	O
determinants	O
,	O
including	O
OCT1	O
,	O
a	O
physiologically	O
based	O
pharmacokinetic	B:C0201734
(	I:C0201734
PBPK	I:C0201734
)	I:C0201734
model	I:C0201734
of	O
morphine	O
was	O
developed	O
.	O

To	O
further	O
explore	O
the	O
underlying	O
mechanisms	O
for	O
variability	O
arising	O
from	O
relevant	O
determinants	O
,	O
including	O
OCT1	O
,	O
a	O
physiologically	O
based	O
pharmacokinetic	O
(	I:C0201734
PBPK	I:C0201734
)	I:C0201734
model	I:C0201734
of	O
morphine	B:C0026549
was	O
developed	O
.	O

The	O
PBPK	B:C0201734
model	I:C0201734
predicted	O
morphine	O
concentration	O
-	O
time	O
profiles	O
well	O
,	O
in	O
both	O
adults	O
and	O
children	O
.	O

The	O
PBPK	O
model	I:C0201734
predicted	O
morphine	B:C0026549
concentration	O
-	O
time	O
profiles	O
well	O
,	O
in	O
both	O
adults	O
and	O
children	O
.	O

Almost	O
all	O
of	O
the	O
observed	O
morphine	B:C0026549
clearances	O
in	O
pediatric	O
patients	O
fell	O
within	O
a	O
twofold	O
range	O
of	O
median	O
predicted	O
values	O
for	O
each	O
OCT1	O
genotype	O
in	O
each	O
age	O
group	O
.	O

Almost	O
all	O
of	O
the	O
observed	O
morphine	O
clearances	B:C1382187
in	O
pediatric	O
patients	O
fell	O
within	O
a	O
twofold	O
range	O
of	O
median	O
predicted	O
values	O
for	O
each	O
OCT1	O
genotype	O
in	O
each	O
age	O
group	O
.	O

Almost	O
all	O
of	O
the	O
observed	O
morphine	O
clearances	O
in	O
pediatric	O
patients	O
fell	O
within	O
a	O
twofold	O
range	O
of	O
median	O
predicted	O
values	O
for	O
each	O
OCT1	B:C0291786
genotype	O
in	O
each	O
age	O
group	O
.	O

This	O
PBPK	B:C0201734
modeling	I:C0201734
approach	O
quantitatively	O
demonstrates	O
that	O
OCT1	O
genotype	O
,	O
age	O
-	I:C0018270
related	I:C0018270
growth	I:C0018270
,	O
and	O
changes	O
in	O
blood	O
flow	I:C0232338
as	O
important	O
contributors	O
to	O
morphine	O
pharmacokinetic	O
(	O
PK	O
)	O
variability	O
.	O

This	O
PBPK	O
modeling	I:C0201734
approach	O
quantitatively	O
demonstrates	O
that	O
OCT1	B:C0291786
genotype	O
,	O
age	O
-	I:C0018270
related	I:C0018270
growth	I:C0018270
,	O
and	O
changes	O
in	O
blood	O
flow	I:C0232338
as	O
important	O
contributors	O
to	O
morphine	O
pharmacokinetic	O
(	O
PK	O
)	O
variability	O
.	O

This	O
PBPK	O
modeling	I:C0201734
approach	O
quantitatively	O
demonstrates	O
that	O
OCT1	O
genotype	O
,	O
age	B:C0018270
-	I:C0018270
related	I:C0018270
growth	I:C0018270
,	O
and	O
changes	O
in	O
blood	O
flow	I:C0232338
as	O
important	O
contributors	O
to	O
morphine	O
pharmacokinetic	O
(	O
PK	O
)	O
variability	O
.	O

This	O
PBPK	O
modeling	I:C0201734
approach	O
quantitatively	O
demonstrates	O
that	O
OCT1	O
genotype	O
,	O
age	O
-	I:C0018270
related	I:C0018270
growth	I:C0018270
,	O
and	O
changes	O
in	O
blood	B:C0232338
flow	I:C0232338
as	O
important	O
contributors	O
to	O
morphine	O
pharmacokinetic	O
(	O
PK	O
)	O
variability	O
.	O

This	O
PBPK	O
modeling	I:C0201734
approach	O
quantitatively	O
demonstrates	O
that	O
OCT1	O
genotype	O
,	O
age	O
-	I:C0018270
related	I:C0018270
growth	I:C0018270
,	O
and	O
changes	O
in	O
blood	O
flow	I:C0232338
as	O
important	O
contributors	B:C1257890
to	O
morphine	O
pharmacokinetic	O
(	O
PK	O
)	O
variability	O
.	O

This	O
PBPK	O
modeling	I:C0201734
approach	O
quantitatively	O
demonstrates	O
that	O
OCT1	O
genotype	O
,	O
age	O
-	I:C0018270
related	I:C0018270
growth	I:C0018270
,	O
and	O
changes	O
in	O
blood	O
flow	I:C0232338
as	O
important	O
contributors	O
to	O
morphine	B:C0026549
pharmacokinetic	O
(	O
PK	O
)	O
variability	O
.	O

